Ziv Medical Center, Safed, Israel.
Department of Urology, Weill Cornell Medicine/New York-Presbyterian Hospital, 525 E. 68Th Street, New York, NY, 10021, USA.
World J Urol. 2023 Apr;41(4):1141-1146. doi: 10.1007/s00345-023-04319-w. Epub 2023 Feb 17.
The Butterfly Prostatic Retraction Device ("Butterfly") is a permanent nitinol implant for benign prostatic hyperplasia. This study examines the chronic response of prostate tissue to the Butterfly in histological specimens from patients in the Butterfly pilot clinical study.
Retrospective qualitative and semi-quantitative review of histological specimens of seven (7) patients who participated in the Butterfly pilot clinical study. Patients had at least 1-month implantation with the Butterfly prior to implant removal and TURP. Tissue samples were graded by two pathologists.
Four out of six patients had IPSS decreased from baseline. All seven patients' samples had signs of chronic inflammation; one demonstrated acute inflammation and one demonstrated fibrosis. In three cases, intraglandular calcification was identified. There was no ischemic necrosis induced by the implant, and no encrustation, urethral edema, or cellular atypia was noted.
The Butterfly demonstrated an overall favorable safety profile in terms of tissue response. This study demonstrates that there is no significant tissue reaction in the prostatic urethra due to presence of Butterfly device.
蝴蝶前列腺回缩装置(“蝴蝶”)是一种用于治疗良性前列腺增生的永久性镍钛诺植入物。本研究通过对参加蝴蝶先导临床研究的患者的组织标本进行组织学检查,研究前列腺组织对蝴蝶的慢性反应。
对参加蝴蝶先导临床研究的 7 名患者的组织标本进行回顾性定性和半定量分析。在进行植入物取出和 TURP 之前,患者至少有 1 个月的蝴蝶植入。由两名病理学家对组织样本进行分级。
6 名患者中有 4 名患者的 IPSS 从基线下降。7 名患者的样本均有慢性炎症的迹象;1 例表现为急性炎症,1 例表现为纤维化。在 3 例中,发现了腺体内钙化。植入物未引起缺血性坏死,也未发现结石、尿道水肿或细胞异型性。
就组织反应而言,蝴蝶的总体安全性良好。本研究表明,由于蝴蝶装置的存在,前列腺尿道内没有明显的组织反应。